$BSX Boston Scientific Tape Reports
Per Ticker.id: $BSX Boston Scientific Tape Reports — 8 podcast mentions across 4 podcasts (30 days), latest 2026-08-26 16:00 UTC.
Here are 3 big movers we are watching. Citi opening a positive catalyst watch on Oracle, saying they see shares moving higher thanks to continued demand for the company's AI products after, quote, one of the most extreme dislocations and drawdowns in the stock's history. Don't miss the analyst behind that call with us next hour. Currently, Oracle shares up by about 2%. Meantime, Boston Scientific is under pressure after reporting a cybersecurity incident that they say is expected to cause, quote, disruptions and limitations to access to company products, and that a, quote, timeline for full restoration is not yet known. Those shares down nearly 5%. And watch Intuit under pressure as well, but well off the lows after guidance came in below expectations there. JPMorgan downgrading that stock to neutral and cutting its price target in nearly half.
Leslie Picker — Squawk on the Street · 10AM Hour: Nvidia Ahead, Meta Settles, & PCE Comes In Hot 8/26/26 · 2026-08-26Mandeep Singh of Bloomberg Intelligence. And ahead of the earnings, Nvidia shares are little changed, as is the broader market. S&P futures are down nearly a tenth percent. Dow futures, little change to the upside, and Nasdaq futures showing a two-tenths of 1% decline. This morning we heard from Kohl's, a beat and raise quarter for the department store chain, but it says still sees $350 to $400 million in capital spending this year. Kohl's shares in the premarket are down nearly 4%, and Boston Scientific is down nearly 3.5%. The biotech says it's identified an ongoing cybersecurity incident, and a timeline for full restoration is still unknown. The world continues to mourn Dolly Parton. The country music icon and philanthropist died yesterday after a brief fight with cancer. We spoke with Dolly in 2014 about what kept her on the road for more than half a century. We've been to Europe, we've been to Australia, New Zealand, and certainly we've been all over America.
Nathan Hager — Bloomberg News Now · US Weighs More Canada Measures, Iran Hormuz Talks · 2026-08-26It trades exactly the same way in terms of the dollar, you know, the dollar relationship as the other ones. So I'm like, 'Well, if they're just going to give away oil,' and, and they're, you know— so I went out and bought Occidental Petroleum. I mean, you know, if it's good enough for Warren Buffett, then it's good enough for me. And if, especially when I'm trying to look for something in that space. So I mean, look, I've made a lot of terrible choices too. I bought Boston Scientific at a horrible price and I sold it at even worse price. I did the same thing with Zoetis. I mean, you're not gonna get them all, but you know, if you can get most of them right, you know, you hopefully you make more money than you lose in the end.
Michael Kramer — Investing Experts · Hedging exposure in this volatile market · 2026-08-20Would you say there are lessons that you learned with the, that those Boston Scientific and Zoetis.
Rena — Investing Experts · Hedging exposure in this volatile market · 2026-08-20What I do is I create like a watch list and I just watch stocks for sometimes a year or two, even understanding the story, understanding how the stock reacts, understanding what it's doing, understanding the drivers, and looking for that moment where there's a really good opportunity where everything just comes together. So like Boston Scientific, I had watched it for 2 years go nothing but up, and it looked like it had been consolidating for a year. It looked like technically it was getting ready for a big move. Unfortunately, it moved big, but it moved big in the direction that I didn't expect. So I got that part right, but the direction wrong. But fundamentally, it made sense, right? I mean, the fundamentals seemed okay. The story was intact. And then they come out and they report earnings that caught everyone off guard. No one expected one part of their business to disappoint. It did. And I like to try to give things two quarters in a row to prove the market wrong. So Boston Scientific came out. I think I bought it in the '90s and it came out, reported a really bad quarter. It went down a lot. I held on to it because I'm like, you know, this could just be a one-quarter thing. Like, I don't know, but the market moves so quickly, it doesn't really give someone the opportunity to try to, you know, give it time to work itself out. So, you know, the stock went down 20 or 30%, I held on to it. Next quarter comes, it's bad again, the stock goes down again. I'm done, I'm out. That's it. You know, 2 quarters in a row I lost 30, 40%. Now I'm just moving on. But, you know, in fairness, what if the quarter had been good, right? The stock could have been right back to where it was when I originally bought it. So that's why I always try to give things like 2 quarters in a row. And the same thing with Zoetis. It had reported, you know, 2 bad quarters in a row. I lost— was losing money in it. It was coming to the end of the year. I had capital gains. So Goodbye, Zoetis. You know, you didn't make me money. I'm losing money now.
Michael Kramer — Investing Experts · Hedging exposure in this volatile market · 2026-08-20Now, from time to time, we receive questions submitted via our website, and here's one that came in today. Says, could you please analyze Boston Scientific? BSX is the symbol. I would greatly appreciate it. So despite what our previous caller said, that healthcare stocks had been doing really well, they all aren't because Boston Scientific is down considerably, down 52% from its 52-week high, even though it has bounced recently from a low around $43 to around $52 right now. But this is the perfect example of a name where it was growing nicely, made $0.96 in 2020, and that increased all the way up to $3.06 last year, up 22% earnings growth. But this year earnings growth is only up 6 or 8 and revenue growth up 6. And next year expectation is for earnings growth 4, as well as revenue growth at 4. Whenever you see growth decelerate dramatically, you get this multiple contraction. So that's the positive here. This isn't down because of the business struggling, it's just slowing. And I'm, I'm okay with that. Now if I go look at the numbers, still $75 billion market cap. It is back to kind of where it broke out in 2023 or in this $50 range. And so from the technical perspective, this is pretty good. $3.6 billion market cap— sorry, free cash flow. $75 billion market cap. And it's probably valued even around 13. Let me see where this normally trades, kind of pre— I mean, it's still— it's actually pretty cheap all time because what it looks like is Despite earnings growth slowing, free cash flow is near an all-time high. So where's the beef here? I actually kind of like this. I actually kind of like this. And for everyone else out there, Boston Scientific, they develop, manufacture, and market cardiology, endoscope, intervention, urology. Could this be a GLP-1 casualty? Potentially, right? People losing weight. Having less heart attacks, heart issues, et cetera. That's certainly possible, but that is not reflecting in the cash flow of the business. Still very good. So I kind of like it. Let me give Boston Scientific a thumbs up. Now let's talk about how much money you need to make you happy. Now this is going to inform your investment choices. So there's an old adage about rolling a dice.
Justin Klein — InvestTalk · Soft Jobs Report and the Dollar's New Direction: What It Means for Investors · 2026-08-15